Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation Indian Medical PG Practice Questions and MCQs

Question 271: Which of the following is an anticoagulant drug?

A. Heparin
B. Ximelagatran
C. Fondaparinux
D. All of these (Correct Answer)

Explanation: **Explanation:** Anticoagulants are drugs that prevent the formation of fibrin clots by interfering with the coagulation cascade [3]. The correct answer is **All of these** because each drug listed acts on different steps of the clotting pathway to achieve anticoagulation. * **Heparin (Option A):** An indirect thrombin inhibitor. It acts by binding to **Antithrombin III (AT-III)**, which then inactivates Factor Xa and Thrombin (Factor IIa) [2]. It is the drug of choice for rapid anticoagulation (e.g., in PE or DVT) [3]. * **Ximelagatran (Option B):** A prodrug of melagatran, which is a **Direct Thrombin Inhibitor (DTI)** [3]. While it was the first oral DTI, it was largely withdrawn due to hepatotoxicity and replaced by Dabigatran. However, it remains classified as an anticoagulant. * **Fondaparinux (Option C):** A synthetic pentasaccharide that acts as a **selective Factor Xa inhibitor** [1]. Like heparin, it requires AT-III to function, but it is too short to bridge AT-III to thrombin, making it specific for Factor Xa [2]. **High-Yield Clinical Pearls for NEET-PG:** 1. **Antidotes:** The antidote for Heparin is **Protamine Sulfate** [4]. There is no specific antidote for Fondaparinux. 2. **Monitoring:** Heparin is monitored using **aPTT**, whereas Fondaparinux and Direct Oral Anticoagulants (DOACs) generally do not require routine monitoring. 3. **HIT:** Fondaparinux does not cause Heparin-Induced Thrombocytopenia (HIT) and can be used as an alternative treatment for it [4]. 4. **LMWH vs. Heparin:** LMWH (e.g., Enoxaparin) has a higher ratio of Anti-Xa to Anti-IIa activity compared to Unfractionated Heparin (1:1).

Question 272: Which of the following anticoagulants is indicated for atrial fibrillation in a patient with a prior history of stroke, with a reduced risk of hemorrhage?

A. Vitamin K antagonists
B. Apixaban (Correct Answer)
C. Clopidogrel
D. Ticlopidine

Explanation: **Explanation:** **Apixaban** is the correct answer because it belongs to the class of **Direct Oral Anticoagulants (DOACs)**, specifically a direct **Factor Xa inhibitor**. In the landmark ARISTOTLE trial, Apixaban was found to be superior to Warfarin in preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF), while significantly reducing the risk of major bleeding (especially intracranial hemorrhage). This makes it a preferred choice for secondary stroke prevention in AF patients. **Analysis of Incorrect Options:** * **Vitamin K Antagonists (e.g., Warfarin):** While effective for stroke prevention in AF, they have a narrow therapeutic index, require frequent INR monitoring, and carry a higher risk of life-threatening hemorrhagic complications compared to DOACs like Apixaban. * **Clopidogrel & Ticlopidine:** These are **antiplatelet agents** (P2Y12 inhibitors). While they are used in coronary artery disease and certain stroke subtypes, they are significantly less effective than anticoagulants for preventing cardioembolic strokes caused by atrial fibrillation. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Apixaban and Rivaroxaban inhibit Factor Xa; Dabigatran is a direct thrombin (Factor IIa) inhibitor. * **Reversal Agent:** The specific reversal agent for Apixaban and Rivaroxaban is **Andexanet alfa**. For Dabigatran, it is **Idarucizumab**. * **Contraindication:** DOACs are generally avoided in patients with **valvular AF** (moderate-to-severe mitral stenosis or mechanical heart valves); Warfarin remains the drug of choice in these cases. * **Renal Dosing:** Apixaban is the DOAC least dependent on renal clearance, making it safer in mild-to-moderate chronic kidney disease.

Question 273: Which of the following is a direct fibrinolytic agent?

A. Prourokinase
B. Alteplase (Correct Answer)
C. Recombinant tissue plasminogen activator (rt-PA)
D. All of the above

Explanation: **Explanation:** Fibrinolytic agents (thrombolytics) are drugs used to dissolve pre-formed clots by converting plasminogen into plasmin, which then degrades fibrin [1]. These agents are categorized based on their mechanism of action into **Direct** and **Indirect** activators. **1. Why Alteplase is the Correct Answer:** Alteplase is a **direct-acting** fibrinolytic. It is a naturally occurring serine protease that directly binds to fibrin and converts the clot-bound plasminogen into plasmin [1]. Because it has a high affinity for fibrin, it is considered "clot-specific," meaning it primarily activates plasminogen at the site of the thrombus, reducing the risk of systemic lytic states compared to older agents like Streptokinase. **2. Analysis of Incorrect Options:** * **Prourokinase:** This is a **precursor** (zymogen) of urokinase. It requires conversion into its active form (urokinase) to exert its effect; therefore, it is not considered a primary direct activator in the same clinical context as Alteplase. * **Recombinant tissue plasminogen activator (rt-PA):** While Alteplase *is* an rt-PA, in the context of standardized medical examinations like NEET-PG, "Alteplase" is the specific pharmacological name of the drug molecule. Option C is a general class description rather than a specific agent name. * **All of the above:** This is incorrect because the pharmacological classification distinguishes between precursors and active direct enzymes. **High-Yield Clinical Pearls for NEET-PG:** * **Streptokinase** is an **indirect** activator; it must first form a complex with plasminogen to expose the active site. It is also antigenic (derived from *Streptococci*). * **Tenecteplase** is the most fibrin-specific agent and has the longest half-life, allowing for single bolus dosing [2]. * **Absolute Contraindications:** Previous hemorrhagic stroke, active internal bleeding, or recent intracranial neoplasm. * **Antidote:** Epsilon-aminocaproic acid or Tranexamic acid (plasminogen activation inhibitors).

Question 274: What is the primary indication for initiating intramuscular iron therapy?

A. Pregnancy
B. Postpartum period
C. Emergency surgery
D. Oral iron intolerance (Correct Answer)

Explanation: **Explanation:** The primary indication for parenteral iron therapy (intramuscular or intravenous) is the **inability to tolerate or absorb oral iron**. Oral iron is the first-line treatment for iron deficiency anemia due to its safety and low cost. However, many patients experience significant gastrointestinal side effects (nausea, abdominal cramps, constipation, or diarrhea) or have malabsorption syndromes (e.g., Celiac disease, post-gastrectomy), making oral therapy ineffective or impossible. **Analysis of Options:** * **Oral iron intolerance (Correct):** This is the most common clinical reason to switch to parenteral routes. If the patient cannot take the medication, the deficiency cannot be corrected. * **Pregnancy (Incorrect):** Oral iron is the standard of care during pregnancy. Parenteral iron is reserved only for severe anemia in late pregnancy or when oral iron fails/is not tolerated. * **Postpartum period (Incorrect):** Routine postpartum anemia is managed with oral iron unless there is severe hemodynamic instability or significant blood loss requiring transfusion. * **Emergency surgery (Incorrect):** Parenteral iron takes 1–2 weeks to significantly raise hemoglobin levels. In an emergency surgical setting with acute blood loss, **blood transfusion** is the treatment of choice for immediate stabilization. **High-Yield NEET-PG Pearls:** * **Rate of Response:** Parenteral iron does **not** raise hemoglobin levels faster than oral iron; it only replenishes iron stores more rapidly. * **Calculation:** The total dose of parenteral iron required is calculated using the **Ganzoni Formula**: *Body weight (kg) × (Target Hb - Actual Hb) × 2.4 + Iron stores (500mg).* * **Adverse Effects:** The most serious risk of IM/IV iron is **anaphylaxis**. For IM injections, the **Z-track technique** must be used to prevent skin staining.

Question 275: What is the primary function of NADPH in red blood cells?

A. To produce ATP (Correct Answer)
B. To stabilize the red blood cell membrane
C. To facilitate reductive biosynthesis
D. To prevent G6PD deficiency

Explanation: **Explanation:** The primary function of **NADPH** (Nicotinamide Adenine Dinucleotide Phosphate) in red blood cells is to maintain a pool of **reduced glutathione**, which is essential for neutralizing reactive oxygen species (ROS) like hydrogen peroxide [2]. 1. **Why Option C is Correct (Reductive Biosynthesis):** In the context of general biochemistry, NADPH is the universal electron donor for **reductive biosynthesis** (e.g., fatty acid and steroid synthesis) [1]. In RBCs, specifically, it provides the reducing equivalents necessary to convert oxidized glutathione (GSSG) back to reduced glutathione (GSH) via the enzyme *Glutathione Reductase* [2]. This protects hemoglobin and membrane lipids from oxidative damage [2]. 2. **Why other options are incorrect:** * **Option A:** ATP in RBCs is produced via the **Embden-Meyerhof pathway** (anaerobic glycolysis), not by NADPH. * **Option B:** While NADPH indirectly helps maintain membrane integrity by preventing lipid peroxidation, its primary biochemical role is as a reducing agent [1], [2]. * **Option D:** NADPH does not prevent G6PD deficiency; rather, G6PD is the enzyme required to *produce* NADPH via the Hexose Monophosphate (HMP) Shunt [2]. **NEET-PG High-Yield Pearls:** * **G6PD Deficiency:** The most common enzymopathy worldwide. Since RBCs lack mitochondria, the **HMP Shunt** is their *only* source of NADPH [2]. * **Heinz Bodies:** Denatured hemoglobin precipitates formed due to oxidative stress in the absence of sufficient NADPH/Glutathione [2]. * **Bite Cells:** Formed when splenic macrophages pluck out Heinz bodies from RBCs. * **Drug Triggers:** Oxidative drugs like **Primaquine, Sulfonamides, Dapsone, and Nitrofurantoin** can precipitate hemolysis in G6PD-deficient individuals [2].

Question 276: Platelet aggregation is blocked by aspirin due to its action on which of the following?

A. Prostacyclin
B. Prostaglandin F2 alpha
C. Thromboxane A2 (Correct Answer)
D. Phospholipase C

Explanation: **Explanation:** **Mechanism of Action:** Aspirin (Acetylsalicylic acid) acts by **irreversibly inhibiting the enzyme Cyclooxygenase-1 (COX-1)**. In platelets, this inhibition prevents the conversion of arachidonic acid into **Thromboxane A2 (TXA2)**. TXA2 is a potent vasoconstrictor and a key mediator that promotes platelet aggregation and degranulation. Since platelets are anucleated and cannot synthesize new enzymes, the inhibitory effect of aspirin lasts for the entire lifespan of the platelet (approx. 7–10 days). **Analysis of Incorrect Options:** * **Option A (Prostacyclin/PGI2):** Produced by vascular endothelial cells, PGI2 inhibits platelet aggregation. While high-dose aspirin can inhibit PGI2, the low-dose antiplatelet effect specifically targets TXA2 to favor an anti-thrombotic state. * **Option B (Prostaglandin F2 alpha):** This prostaglandin is primarily involved in uterine contraction and bronchoconstriction; it does not play a primary role in platelet aggregation. * **Option D (Phospholipase C):** This is an enzyme involved in the second messenger system (IP3/DAG pathway). Aspirin does not act on this enzyme; it acts downstream on the COX pathway. **NEET-PG High-Yield Pearls:** * **Low-dose Aspirin (75–150 mg):** Exhibits "selective" antiplatelet action by inhibiting TXA2 without significantly suppressing endothelial PGI2. * **Secondary Prevention:** Aspirin is the drug of choice for secondary prophylaxis of Myocardial Infarction (MI) and Ischemic Stroke. * **Platelet Turnover:** Surgery is usually delayed for 7 days after stopping aspirin to allow for the generation of new, functional platelets. * **Other Antiplatelets:** Note that Clopidogrel/Prasugrel act on **P2Y12 (ADP) receptors**, while Abciximab acts on **GP IIb/IIIa receptors**.

Question 277: What is the anticoagulant of choice for prophylaxis of venous thromboembolism in a patient undergoing cancer surgery?

A. Heparin sulfate
B. Protamine sulfate
C. Low molecular weight heparin (Correct Answer)
D. Warfarin

Explanation: ### Explanation **Correct Option: C. Low Molecular Weight Heparin (LMWH)** In patients undergoing major cancer surgery, there is a significantly high risk of venous thromboembolism (VTE) due to the prothrombotic nature of malignancy and the surgical trauma. **LMWH (e.g., Enoxaparin, Dalteparin)** is the anticoagulant of choice for prophylaxis because: * **Predictable Pharmacokinetics:** It has better bioavailability and a longer half-life than unfractionated heparin (UFH). * **Safety & Efficacy:** It is as effective as UFH but carries a lower risk of Heparin-Induced Thrombocytopenia (HIT) and osteoporosis. * **Convenience:** It allows for once-daily subcutaneous dosing without the need for routine laboratory monitoring (aPTT). **Analysis of Incorrect Options:** * **A. Heparin Sulfate:** This is a naturally occurring glycosaminoglycan found on cell surfaces, not a therapeutic drug. The drug used is Unfractionated Heparin (UFH). While UFH can be used for prophylaxis, LMWH is preferred due to its superior safety profile and ease of administration. * **B. Protamine Sulfate:** This is the **antidote** used to reverse the effects of heparin (heparin antagonist). It is not an anticoagulant and would increase the risk of thrombosis if given in this scenario. * **D. Warfarin:** This is an oral vitamin K antagonist. It is not preferred for immediate perioperative prophylaxis because it has a slow onset of action (requires 3–5 days to reach therapeutic levels) and carries a high risk of bleeding complications during surgery. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** LMWH mainly inhibits **Factor Xa** (Ratio of Xa:IIa inhibition is 3:1), whereas UFH inhibits both Xa and IIa equally (1:1). * **Monitoring:** If monitoring is required (e.g., in renal failure or pregnancy), **Anti-Factor Xa levels** are measured, not aPTT. * **Renal Caution:** LMWHs are primarily excreted renally; thus, dose adjustment or switching to UFH is necessary in patients with severe renal impairment (CrCl <30 ml/min).

Question 278: All of the following statements about Heparin are true, except:

A. Causes Alopecia
B. Non Teratogenic
C. Releases Lipoprotein Lipase
D. Causes Hypokalemia (Correct Answer)

Explanation: **Explanation:** The correct answer is **D (Causes Hypokalemia)** because Heparin actually causes **Hyperkalemia**, not hypokalemia. **Mechanism of Hyperkalemia:** Heparin inhibits the synthesis of **Aldosterone** in the adrenal cortex (by reducing the number and affinity of angiotensin II receptors in the zona glomerulosa). Since aldosterone is responsible for sodium reabsorption and potassium excretion, its suppression leads to potassium retention, resulting in hyperkalemia. This effect can occur even with low-dose prophylactic heparin. **Analysis of Other Options:** * **A. Causes Alopecia:** True. Transient alopecia (hair loss) is a documented, though less common, side effect of heparin therapy, typically occurring 1–4 months after starting treatment. * **B. Non-Teratogenic:** True. Heparin is a large, polar polysaccharide molecule that **does not cross the placenta**. Therefore, it is the anticoagulant of choice during pregnancy (unlike Warfarin, which is teratogenic). * **C. Releases Lipoprotein Lipase:** True. Heparin clears lipemic plasma by releasing the enzyme lipoprotein lipase from the vascular endothelium into the circulation. This enzyme breaks down triglycerides into free fatty acids. **NEET-PG High-Yield Pearls:** * **Antidote:** Protamine Sulfate (1 mg neutralizes 100 units of heparin). * **Monitoring:** aPTT (Activated Partial Thromboplastin Time). * **Most Common Side Effect:** Bleeding/Hemorrhage. * **Serious Immune Side Effect:** Heparin-Induced Thrombocytopenia (HIT), caused by antibodies against the Heparin-Platelet Factor 4 (PF4) complex. * **Long-term Use:** Can lead to **Osteoporosis**.

Question 279: Which of the following drugs crosses the placenta?

A. Heparin
B. Warfarin (Correct Answer)
C. Dicumarol
D. Nicoumalone

Explanation: **Explanation:** The ability of a drug to cross the placenta is primarily determined by its molecular weight and lipid solubility. **1. Why Warfarin is Correct:** Warfarin is a low-molecular-weight, lipid-soluble organic acid. Due to these properties, it easily crosses the placental barrier. When administered during pregnancy, especially during the first trimester (6–9 weeks), it is highly teratogenic, leading to **Fetal Warfarin Syndrome** (characterized by nasal hypoplasia, stippled epiphyses, and CNS defects). In later stages, it can cause fetal hemorrhage and death. **2. Why the other options are incorrect:** * **Heparin (Option A):** Heparin is a large, highly polar, and negatively charged mucopolysaccharide. Because of its **high molecular weight**, it cannot cross the placenta. Therefore, Heparin (specifically LMWH) is the **anticoagulant of choice during pregnancy**. * **Dicumarol and Nicoumalone (Options C & D):** While these are also oral anticoagulants (coumarin derivatives) that can cross the placenta, **Warfarin** is the prototypical drug and the most clinically significant answer in the context of pharmacology exams. In many competitive formats, if multiple coumarins are listed, Warfarin is the standard representative of the class. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice in Pregnancy:** Low Molecular Weight Heparin (LMWH) like Enoxaparin is preferred because it does not cross the placenta and has a predictable profile. * **Warfarin Teratogenicity:** It is a Category X drug. The most sensitive period is the 6th to 9th week of gestation. * **Breastfeeding:** Unlike its placental transfer, Warfarin is highly protein-bound and does not enter breast milk in significant amounts, making it generally safe for nursing mothers (unlike Heparin). * **Mnemonic:** **H**eparin is **H**eavy (High MW) and stays in the mother; **W**arfarin is **W**icked (crosses placenta and causes birth defects).

Question 280: Heparin is the commonly used anticoagulant in cardiac surgery. Which of the following statements about heparin is FALSE?

A. It is the weakest acid found in living things. (Correct Answer)
B. Most commercial preparations of heparin now utilize pig intestinal mucosa.
C. It acts via Antithrombin activation.
D. It can produce thrombocytopenia.

Explanation: ### Explanation **1. Why Option A is the Correct (False) Statement:** Heparin is actually the **strongest organic acid** found in the human body, not the weakest. It is a highly sulfated glycosaminoglycan with a high negative charge density [1]. This strong acidity is fundamental to its pharmacological action, as it allows heparin to bind to various proteins and enzymes [1]. **2. Analysis of Incorrect Options (True Statements):** * **Option B:** Historically, heparin was obtained from beef lungs, but modern commercial preparations primarily utilize **porcine (pig) intestinal mucosa** due to higher yield and lower risk of prion diseases [4]. * **Option C:** Heparin acts as an indirect anticoagulant. It binds to **Antithrombin III (AT-III)**, inducing a conformational change that accelerates the inactivation of Factor Xa and Thrombin (Factor IIa) by 1,000 to 10,000 times [1], [3]. * **Option D:** **Heparin-Induced Thrombocytopenia (HIT)** is a significant side effect [4]. Type II HIT is an immune-mediated reaction where antibodies form against the Heparin-Platelet Factor 4 (PF4) complex, leading to paradoxically increased risk of thrombosis despite low platelet counts. **3. High-Yield Clinical Pearls for NEET-PG:** * **Antidote:** Protamine sulfate (a strong base) neutralizes heparin (a strong acid) via chemical antagonism [2]. * **Monitoring:** The effect of Unfractionated Heparin (UFH) is monitored using **aPTT** (Target: 1.5–2.5 times the control). * **Drug of Choice:** Heparin is the anticoagulant of choice during **pregnancy** (it does not cross the placenta) and in **cardiac bypass surgery** (due to its rapid onset and reversibility) [2]. * **LMWH vs. UFH:** Low Molecular Weight Heparin (e.g., Enoxaparin) mainly inhibits Factor Xa and does not require routine aPTT monitoring [5].

Practice by Chapter

Hematopoietic Growth Factors

Practice Questions

Iron Preparations and Management of Iron Deficiency

Practice Questions

Vitamin B12 and Folic Acid

Practice Questions

Anticoagulants: Heparins and Direct Inhibitors

Practice Questions

Oral Anticoagulants

Practice Questions

Antiplatelet Drugs

Practice Questions

Thrombolytic Agents

Practice Questions

Hemostatic Drugs

Practice Questions

Plasma Expanders

Practice Questions

Blood Transfusion and Alternatives

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free